Abstract: The present invention relates to the synthesis of a novel compound, in which liquid hydrazine and the derivatives thereof react with excess carbon dioxide to enable the carbon dioxide to chemically bond to the hydrazine and the derivatives thereof. To this end, high-pressure carbon dioxide is used to synthesize hydrazine and the derivatives thereof to which the carbon dioxide is bonded in a pure form with no water and no by-product. Furthermore, the present invention provides a method for utilizing the above-described compounds by reacting the compounds with carbonyl compounds.

Abstract: Compounds having PDE10A inhibitory activity and having general formula (I), or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient.

Abstract: A process for recovering and using an carboxylic acid derived from a fermentation broth by means of making an ester of the free carboxylic acid and alcohol in carbon dioxide (CO2) without the presence of any other acid catalyst at a reaction temperature and pressure that corresponds to supercritical, critical or near critical conditions for the alcohol and/or CO2 is described. The process can constitute part of a general process of refining carboxylic acids derived from a fermentation broth for use in the production of a variety of chemical compounds, such as C4 platform compounds, polymers, or fuels.

Abstract: This disclosure relates to a process for preparing D,L-methionine by feeding carbon dioxide to an aqueous potassium methioninate solution obtained by hydrolysis of 5-(2-methylmercaptoethyl)hydantoin, in order to precipitate out crude methionine, which is separated off and purified. In this process an aqueous solution of the separated-off crude methionine is purified by recrystallization from a solution containing potassium ions and also a crystallization additive. The crystallization additive is a nonionic or anionic surfactant, or a mixture of different nonionic or anionic surfactants. The recrystallization occurs by introducing a 60 to 110° C.-hot methionine solution into a 35 to 80° C.-warm methionine suspension, a temperature of which is lower than that of the introduced solution, such that the temperature of the methionine suspension being maintained between 35 and 80° C. during the addition. The crystallization additive is a sorbitan fatty acid ester or a mixture of different sorbitan fatty acid esters.

Abstract: The description provides processes for the regio and stereospecific synthesis of polyprenylatedquinone derivatives, such as Vitamin K1, K2 and Ubiquinone, exploiting dithioacetals, especially 1,3-dithiane, mediated Umpolung chemistry which works along a new concept “Inhibiting resonance delocalization (IRD)” to overcome isomerization generated due to delocalization of allyliccarbanion on the ?-electron cloud of an allylic systems by the conventional synthesis.

Abstract: A process for producing high purity acetic acid from a carbonylation reaction, wherein the carbonylation reaction is carried out while maintaining a low ethyl iodide content in the reaction medium. The ethyl iodide concentration may be maintained by removing acetaldehyde from the reaction medium and/or by adjusting at least one A) hydrogen partial pressure in the reactor, B) methyl acetate concentration of the reaction medium; and/or C) methyl iodide concentration of the reaction medium.

Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Abstract: Methods for removing contaminants from algal oil are provided. In an embodiment, a method comprises the steps of combining a sulfuric acid-aqueous solution that has a pH of about 1 or less with a contaminant-containing algal oil at treatment conditions effective to form an effluent. The effluent comprises a treated algal oil phase and contaminants in an acidic aqueous phase. The contaminants comprise metals, phosphorus, or combinations thereof. The acidic aqueous phase is removed from the effluent to form a contaminant-depleted algal oil.

Abstract: An ionic liquid is used as liquid matrix for organic synthesis in homogeneous phase on soluble support, the ionic liquid being presented in liquid or solid form at ambient temperature, of formula A1+X1?, A1+ representing a cation, functional or non-functional, or a mixture of cations in which either none of the cations is functional or at least one of the cations is functional, and X1? an anion, functional or non-functional, or a mixture of anions in which either none of the anions is functional or at least one of the anions is functional.

Abstract: The present invention relates to a therapeutic agent, wherein the therapeutic agent is D-Boramine. The therapeutic agent is prepared by mixing L-carnitine tartrate, pyridoxal 5? phosphate and fumaric acid. D-Boramine, when administered orally or parenterally in therapeutic quantities, is effective for use in the prevention of cancer that arises from mutations to the BRCA1 and BRCA2 genes, i.e., breast and ovarian and the treatment of several types of human diseases including, but not limited to, Antiphospholipid Syndrome, Disseminate Intravascular Coagulation (DIC), infections arising from viruses (including strains of Human Papillomavirus, Herpes Simplex Virus and Simian Virus), tuberculosis (including XDR Tuberculosis) and mycoplasma, Hepatitis A, B and C, MTHFR genetic mutations.

Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.

Abstract: The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

Abstract: A process is described for preparing 4-haloalkyl-3-mercapto-substituted 2-hydroxybenzoic acid derivatives of the general formula (I) by reaction of 4-thio-substituted ?-keto esters of the formula (II) with alkoxyvinyl haloalkyl ketones of the formula (III) in the presence of a base. In the above formulae, X, R1, R2 and R3 are each hydrogen, halogen, alkyl, alkoxy and cycloalkyl.

Abstract: Described herein are antimicrobial compounds identified via a high-throughput screen to identify compounds that produce anucleate cells in E. coli after cell division occurs. Compound 1 (5-nonyloxytryptamine) and its analogs are small molecule inhibitors of the nucleoid occlusion system and/or proteins that are responsible for maintaining the structure of the chromosome. The antimicrobial compounds are useful to treat bacterial infections as well as to inhibit bacterial growth.

Abstract: Disclosed are a novel reactive mesogen compound having superior thermostability, high birefringence and a simple preparation process while possessing unique liquid crystal characteristics having molecular orientation by forming a polymer network through photopolymerization, and a method of preparing the same. The novel reactive mesogen compound according to the present invention is represented by Formula 3 below.

Abstract: 5-Adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide disclosed in the present disclosure lacks toxicity and can exhibit superior anti-inflammatory effect. It exhibits superior anti-inflammatory effect, for example, by inhibiting the production of one or more of NO and PGE2, by inhibiting the activity of one or more of the transcription factors NF-?B and AP-1 or by inhibiting proinflammatory cytokines such as IL-1?.

Abstract: The present invention provides mild cleansing and cleaning compositions and methods for mitigating irritation induced by harsh detersive surfactants. The invention relates to a method of reducing skin irritation associated with a cleansing composition comprising at least one surfactant, the method comprising combining an effective amount of at least one nonionic amphiphilic polymer with at least one detersive surfactant selected from anionic surfactants, amphoteric surfactants, nonionic surfactants and combinations of two or more thereof.

Abstract: The invention relates to a method for producing halogenated oligomers and/or halogenated polymers of elements of the third to fifth main group, wherein the halogenated oligomers and/or halogenated polymers are synthesized from a first chain-forming agent and a second chain-forming agent in a plasma-chemical reaction. At least one of the two chain-forming agents is a halogen compound of an element of the third to fifth main group.

Abstract: Disclosed is a process for producing an oxide catalyst for use in the gas-phase catalytic oxidation reaction or the like of propane or the like, the process comprising the steps of: (I) obtaining a preparation containing compounds of Mo, V, Nb, and Sb or Te at the predetermined atomic ratios; (II) drying the preparation to obtain a dry powder; and (III) calcining the dry powder, wherein the step (III) comprises the step of calcining the dry powder in the presence of a compound containing W in the form of a solid to obtain a pre-stage calcined powder or a mainly calcined powder, or the step of calcining the dry powder and calcining the obtained pre-stage calcined powder in the presence of the solid to obtain a mainly calcined powder, the solid satisfies the predetermined conditions, and the oxide catalyst comprises a catalytic component having the predetermined composition.